Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
326.87
+1.12 (0.34%)
Jun 6, 2025, 11:17 AM EDT
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
3.80
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
261.65B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Roche Holding AG News
- 10 hours ago - Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients - Reuters
- 2 days ago - Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - Seeking Alpha
- 2 days ago - Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) - GlobeNewsWire
- 3 days ago - Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study - Benzinga
- 3 days ago - Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says - WSJ
- 3 days ago - Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer - GlobeNewsWire
- 4 days ago - Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer - Business Wire
- 6 days ago - New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer - Benzinga